Log in

NASDAQ:NCNANuCana News Headlines

$6.34
+0.17 (+2.76 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.08
Now: $6.34
$6.38
50-Day Range
$5.35
MA: $5.80
$7.37
52-Week Range
$3.81
Now: $6.34
$12.79
Volume97,117 shs
Average Volume124,184 shs
Market Capitalization$205.92 million
P/E RatioN/A
Dividend YieldN/A
Beta1.11

Headlines

NuCana (NASDAQ NCNA) News Headlines

Source:
DateHeadline
Why NuCana (NCNA) Stock Might be a Great Pick - Yahoo FinanceWhy NuCana (NCNA) Stock Might be a Great Pick - Yahoo Finance
finance.yahoo.com - June 2 at 7:51 PM
Why NuCana (NCNA) Stock Might be a Great Pick - NasdaqWhy NuCana (NCNA) Stock Might be a Great Pick - Nasdaq
www.nasdaq.com - June 2 at 2:51 PM
Why NuCana (NCNA) Stock Might be a Great PickWhy NuCana (NCNA) Stock Might be a Great Pick
finance.yahoo.com - June 2 at 9:50 AM
Will NuCana Continue to Surge Higher? - Yahoo FinanceWill NuCana Continue to Surge Higher? - Yahoo Finance
finance.yahoo.com - June 1 at 10:28 PM
Reviewing NuCana (NASDAQ:NCNA) and Kura Oncology (NASDAQ:KURA)Reviewing NuCana (NASDAQ:NCNA) and Kura Oncology (NASDAQ:KURA)
www.americanbankingnews.com - June 1 at 6:55 PM
Will NuCana Continue to Surge Higher? - NasdaqWill NuCana Continue to Surge Higher? - Nasdaq
www.nasdaq.com - June 1 at 5:28 PM
Top Ranked Momentum Stocks to Buy for May 28th - NasdaqTop Ranked Momentum Stocks to Buy for May 28th - Nasdaq
www.nasdaq.com - May 28 at 5:52 PM
NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference - Yahoo Finance UKNuCana to Present at the 2020 Jefferies Virtual Healthcare Conference - Yahoo Finance UK
uk.finance.yahoo.com - May 28 at 5:52 PM
NuCana plc: NuCana to Present at the 2020 Jefferies Virtual Healthcare ConferenceNuCana plc: NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference
www.finanznachrichten.de - May 28 at 7:43 AM
5 Health Care Stocks to Bet on as Coronavirus Woes Linger - Nasdaq5 Health Care Stocks to Bet on as Coronavirus Woes Linger - Nasdaq
www.nasdaq.com - May 27 at 3:00 PM
NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference - Yahoo FinanceNuCana to Present at the 2020 Jefferies Virtual Healthcare Conference - Yahoo Finance
finance.yahoo.com - May 27 at 3:00 PM
NuCana to Present at the 2020 Jefferies Virtual Healthcare ConferenceNuCana to Present at the 2020 Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 27 at 9:58 AM
NuCana PLC (NASDAQ:NCNA) Given Consensus Rating of "Buy" by BrokeragesNuCana PLC (NASDAQ:NCNA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 27 at 5:03 AM
3 “Strong Buy” Healthcare Stocks That Could Double in the Next Year - Nasdaq3 “Strong Buy” Healthcare Stocks That Could Double in the Next Year - Nasdaq
www.nasdaq.com - May 24 at 1:21 PM
3 “Strong Buy” Healthcare Stocks That Could Double in the Next Year - Yahoo Finance3 “Strong Buy” Healthcare Stocks That Could Double in the Next Year - Yahoo Finance
finance.yahoo.com - May 24 at 8:20 AM
3 “Strong Buy” Healthcare Stocks That Could Double in the Next Year3 “Strong Buy” Healthcare Stocks That Could Double in the Next Year
finance.yahoo.com - May 24 at 8:20 AM
HC Wainwright Reaffirms "Buy" Rating for NuCana (NASDAQ:NCNA)HC Wainwright Reaffirms "Buy" Rating for NuCana (NASDAQ:NCNA)
www.americanbankingnews.com - May 20 at 12:42 PM
NuCana PLC (NASDAQ:NCNA) Expected to Announce Earnings of -$0.26 Per ShareNuCana PLC (NASDAQ:NCNA) Expected to Announce Earnings of -$0.26 Per Share
www.americanbankingnews.com - May 20 at 8:53 AM
NuCana (NASDAQ:NCNA) Releases  Earnings Results, Beats Estimates By $6.20 EPSNuCana (NASDAQ:NCNA) Releases Earnings Results, Beats Estimates By $6.20 EPS
www.americanbankingnews.com - May 20 at 8:19 AM
NuCana Reports First Quarter 2020 Financial Results and Provides Business Update - GlobeNewswireNuCana Reports First Quarter 2020 Financial Results and Provides Business Update - GlobeNewswire
www.globenewswire.com - May 19 at 5:46 PM
NuCana Reports First Quarter 2020 Financial Results and Provides Business UpdateNuCana Reports First Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - May 19 at 5:46 PM
NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 PandemicNuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic
finance.yahoo.com - May 18 at 3:50 PM
NuCana (NCNA) Reports Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic - StreetInsider.comNuCana (NCNA) Reports Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic - StreetInsider.com
www.streetinsider.com - May 18 at 10:50 AM
NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic - GlobeNewswireNuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic - GlobeNewswire
www.globenewswire.com - May 18 at 10:50 AM
NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020
finance.yahoo.com - May 15 at 1:43 PM
NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020 - GlobeNewswireNuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020 - GlobeNewswire
www.globenewswire.com - May 15 at 8:43 AM
NuCana (NCNA) Reports Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121) - StreetInsider.comNuCana (NCNA) Reports Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121) - StreetInsider.com
www.streetinsider.com - May 6 at 4:55 AM
NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121) - GlobeNewswireNuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121) - GlobeNewswire
www.globenewswire.com - May 5 at 5:34 PM
NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121)NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121)
finance.yahoo.com - May 5 at 5:34 PM
BRIEF-Nucana PLC - Believes That Pandemic Will Inevitably Cause Some Delays To Timing Of Initiation And Completion Of Its Clinical Studies - ReutersBRIEF-Nucana PLC - Believes That Pandemic Will Inevitably Cause Some Delays To Timing Of Initiation And Completion Of Its Clinical Studies - Reuters
www.reuters.com - April 2 at 5:37 PM
NuCana (NCNA) Announces Update on Impact of COVID-19 on Clinical Studies - StreetInsider.comNuCana (NCNA) Announces Update on Impact of COVID-19 on Clinical Studies - StreetInsider.com
www.streetinsider.com - April 2 at 5:37 PM
NuCana Provides Update on Impact of COVID-19 on Clinical Studies - GlobeNewswireNuCana Provides Update on Impact of COVID-19 on Clinical Studies - GlobeNewswire
www.globenewswire.com - April 2 at 5:37 PM
NuCana Provides Update on Impact of COVID-19 on Clinical StudiesNuCana Provides Update on Impact of COVID-19 on Clinical Studies
finance.yahoo.com - April 2 at 5:37 PM
NuCana (NASDAQ:NCNA) Is In A Good Position To Deliver On Growth Plans - Yahoo FinanceNuCana (NASDAQ:NCNA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
finance.yahoo.com - March 18 at 1:02 PM
NuCana (NASDAQ:NCNA) Is In A Good Position To Deliver On Growth PlansNuCana (NASDAQ:NCNA) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - March 18 at 1:02 PM
NuCana (NCNA) Reports Prelim. Data from Phase II Study of Single-Agent Acelarin in Patients with Platinum-Resistant Ovarian Cancer - StreetInsider.comNuCana (NCNA) Reports Prelim. Data from Phase II Study of Single-Agent Acelarin in Patients with Platinum-Resistant Ovarian Cancer - StreetInsider.com
www.streetinsider.com - March 11 at 8:01 AM
NuCana plc: NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business UpdateNuCana plc: NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update
www.finanznachrichten.de - March 11 at 12:00 AM
NuCana plc: NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian CancerNuCana plc: NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer
www.finanznachrichten.de - March 11 at 12:00 AM
NuCanas Acelarin shows positive action in mid-stage ovarian cancer studyNuCana's Acelarin shows positive action in mid-stage ovarian cancer study
seekingalpha.com - March 11 at 12:00 AM
NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update - GlobeNewswireNuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update - GlobeNewswire
www.globenewswire.com - March 10 at 6:59 PM
NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian CancerNuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer
finance.yahoo.com - March 10 at 6:59 PM
NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business UpdateNuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update
finance.yahoo.com - March 10 at 6:59 PM
NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer - Yahoo FinanceNuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer - Yahoo Finance
finance.yahoo.com - March 5 at 11:42 AM
60 Stocks Moving In Wednesdays Mid-Day Session - Benzinga60 Stocks Moving In Wednesday's Mid-Day Session - Benzinga
www.benzinga.com - March 4 at 12:43 PM
NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer - GlobeNewswireNuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer - GlobeNewswire
www.globenewswire.com - March 4 at 7:42 AM
NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract CancerNuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer
finance.yahoo.com - March 4 at 7:42 AM
TSLA, INO among premarket gainers - Seeking AlphaTSLA, INO among premarket gainers - Seeking Alpha
seekingalpha.com - March 3 at 11:40 AM
BUZZ-U.S. STOCKS ON THE MOVE-Twitter, Apple, Norwegian Cruise Line, New York Times - NasdaqBUZZ-U.S. STOCKS ON THE MOVE-Twitter, Apple, Norwegian Cruise Line, New York Times - Nasdaq
www.nasdaq.com - March 3 at 6:39 AM
BUZZ-U.S. STOCKS ON THE MOVE-Costco Wholesale, Twitter, Forty Seven, Allied Healthcare - NasdaqBUZZ-U.S. STOCKS ON THE MOVE-Costco Wholesale, Twitter, Forty Seven, Allied Healthcare - Nasdaq
www.nasdaq.com - March 2 at 5:31 PM
Mid-Morning Market Update: Markets Open Higher; Gilead To Buy Forty Seven For $4.9B - BenzingaMid-Morning Market Update: Markets Open Higher; Gilead To Buy Forty Seven For $4.9B - Benzinga
www.benzinga.com - March 2 at 12:31 PM
This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.